pilsicainide has been researched along with Disease Models, Animal in 11 studies
pilsicainide: structure given in first source
pilsicainide : A secondary carboxamide resulting from the formal condensation of the amino group of 2,6-dimethylaniline with the carboxy group of (tetrahydro-1H-pyrrolizin-7a(5H)-yl)acetic acid. It is a sodium channel blocker which is used as an antiarrhythmic drug for the management of atrial tachyarrhythmias in Japan.
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Antiarrhythmic effects and cardiovascular effects of pilsicainide hydrochloride were compared with those of disopyramide in a canine model of coronary ligation-induced ventricular arrhythmias and anesthetized dogs." | 3.70 | [Antiarrhythmic effects of pilsicainide hydrochloride and effects on cardiac function and ECG in dogs: comparison with disopyramide]. ( Hayashi, Y; Hidaka, T; Inomata, N; Inoue, T; Komoriya, K, 2000) |
| "Effects of SUN-1165, a class I antiarrhythmic drug, on ventricular arrhythmias, intraventricular conduction, and the effective refractory period (ERP) were examined in a canine model of myocardial infarction and compared with those of lidocaine." | 3.68 | Effects of SUN-1165, N-(2,6-dimethylphenyl)-8-pyrrolizidine acetamide hydrochloride hemihydrate, a new class I antiarrhythmic drug, on ventricular arrhythmias, intraventricular conduction, and the refractory period in canine myocardial infarction. ( Hashimoto, H; Nakashima, M; Satoh, N, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (9.09) | 18.2507 |
| 2000's | 9 (81.82) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Abrams, RPM | 1 |
| Yasgar, A | 1 |
| Teramoto, T | 1 |
| Lee, MH | 1 |
| Dorjsuren, D | 1 |
| Eastman, RT | 1 |
| Malik, N | 1 |
| Zakharov, AV | 1 |
| Li, W | 1 |
| Bachani, M | 1 |
| Brimacombe, K | 1 |
| Steiner, JP | 1 |
| Hall, MD | 1 |
| Balasubramanian, A | 1 |
| Jadhav, A | 1 |
| Padmanabhan, R | 1 |
| Simeonov, A | 1 |
| Nath, A | 1 |
| Ishiguro, YS | 1 |
| Honjo, H | 1 |
| Opthof, T | 1 |
| Okuno, Y | 1 |
| Nakagawa, H | 1 |
| Yamazaki, M | 1 |
| Harada, M | 1 |
| Takanari, H | 1 |
| Suzuki, T | 1 |
| Morishima, M | 1 |
| Sakuma, I | 1 |
| Kamiya, K | 1 |
| Kodama, I | 1 |
| Dosdall, DJ | 1 |
| Kimura, M | 1 |
| Kobayashi, T | 1 |
| Owada, S | 1 |
| Ashikaga, K | 1 |
| Higuma, T | 1 |
| Sasaki, S | 1 |
| Iwasa, A | 1 |
| Motomura, S | 1 |
| Okumura, K | 1 |
| Niwano, S | 1 |
| Inuo, K | 1 |
| Morohoshi, Y | 1 |
| Nakayama, S | 1 |
| Yuge, M | 1 |
| Imaki, R | 1 |
| Izumi, T | 1 |
| Sugiyama, A | 1 |
| Takahara, A | 1 |
| Honsho, S | 1 |
| Nakamura, Y | 1 |
| Hashimoto, K | 1 |
| Aiba, T | 1 |
| Shimizu, W | 1 |
| Hidaka, I | 1 |
| Uemura, K | 1 |
| Noda, T | 1 |
| Zheng, C | 1 |
| Kamiya, A | 1 |
| Inagaki, M | 1 |
| Sugimachi, M | 1 |
| Sunagawa, K | 1 |
| Morita, H | 1 |
| Zipes, DP | 1 |
| Morita, ST | 1 |
| Wu, J | 1 |
| Deschênes, I | 1 |
| Laurita, KR | 1 |
| Hidaka, T | 1 |
| Inoue, T | 1 |
| Komoriya, K | 1 |
| Hayashi, Y | 1 |
| Inomata, N | 1 |
| Hashimoto, H | 1 |
| Satoh, N | 1 |
| Nakashima, M | 1 |
11 other studies available for pilsicainide and Disease Models, Animal
| Article | Year |
|---|---|
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Dr | 2020 |
Early termination of spiral wave reentry by combined blockade of Na+ and L-type Ca2+ currents in a perfused two-dimensional epicardial layer of rabbit ventricular myocardium.
Topics: Animals; Calcium Channel Blockers; Calcium Channels, L-Type; Disease Models, Animal; Electrophysiolo | 2009 |
Mapping ventricular fibrillation: a simplified experimental model leads to a complicated result.
Topics: Animals; Calcium Channel Blockers; Calcium Channels, L-Type; Disease Models, Animal; Electrophysiolo | 2009 |
Mechanism of ST elevation and ventricular arrhythmias in an experimental Brugada syndrome model.
Topics: Animals; Disease Models, Animal; Dogs; Electrocardiography; Female; In Vitro Techniques; Lidocaine; | 2004 |
Mexiletine protects myocardium during acute ischemia by opening sarcolemmal K-ATP channel: studies in closed-chest acute ischemia model in rabbits.
Topics: Acute Disease; Animals; Anti-Arrhythmia Agents; ATP-Binding Cassette Transporters; Disease Models, A | 2004 |
A simple in vivo atrial fibrillation model of rat induced by transesophageal atrial burst pacing.
Topics: Animals; Atrial Fibrillation; Cardiac Pacing, Artificial; Disease Models, Animal; Electrocardiograph | 2005 |
Cellular basis for trigger and maintenance of ventricular fibrillation in the Brugada syndrome model: high-resolution optical mapping study.
Topics: Action Potentials; Animals; Cardiovascular Agents; Disease Models, Animal; Dogs; Electrocardiography | 2006 |
Temperature modulation of ventricular arrhythmogenicity in a canine tissue model of Brugada syndrome.
Topics: Action Potentials; Animals; Body Temperature; Brugada Syndrome; Disease Models, Animal; Dogs; Electr | 2007 |
How can a single mutation cause such arrhythmic havoc?
Topics: Action Potentials; Animals; Body Temperature; Brugada Syndrome; Disease Models, Animal; Dogs; Electr | 2007 |
[Antiarrhythmic effects of pilsicainide hydrochloride and effects on cardiac function and ECG in dogs: comparison with disopyramide].
Topics: Anesthesia; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Coronary Vessels; Disease Models, | 2000 |
Effects of SUN-1165, N-(2,6-dimethylphenyl)-8-pyrrolizidine acetamide hydrochloride hemihydrate, a new class I antiarrhythmic drug, on ventricular arrhythmias, intraventricular conduction, and the refractory period in canine myocardial infarction.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Disease Models, Animal; Dogs; Electric Stimul | 1992 |